罗氏Roche Holdings（RHHBY）2008年年度报告「OTC」.pdf

1、Roche Annual Report 2008We Innovate Healthcare.Because every life counts.Key figures1 Key figures indexed to 2006=100.2 Proposed by the Board of Directors.3 Development phase I to IV.4 For calculation of the Eco-Efficiency Rate see: ratio%8,8458,3857,365Research and developmentmCHF20082007200611,129

2、10,76710,116Total employee remunerationmCHF13,92414,46811,730 Operating profitmCHF20082007220064,3133,9682,933Total dividendmCHF3,3173,8673,436Income taxesmCHF20082007200680,08078,60474,372Number of employees10,84411,4379,171Net incomemCHF200820072006235,420201,752166,070Patients on clinical trials

3、311.0411.859.86Core Earnings per ShareCHF20082007200677.9567.1949.97Eco-Efficiency Rate 4Roche GroupIndex 2006=1001009011012013014015010090110120130140150Index1Price development of non-voting equity security(Genussschein)|in CHF200150100250300Roche non-voting equity securitySwiss Market Index(rebase

4、d)200620072008Figures for 2006 as in Annual Report 2007.For a full index of Global Reporting Initiative(GRI)indicators used in the report see: in briefGroupRoche reports strong results in a challenging market environment:Group sales up significantly,increasingby 10%in local currencies excluding Tami

5、flu pandemic sales.Strong organic growth of key products more than outweighs lower Tamiflu pandemic sales.Including Tamiflu pandemic sales,Group sales in local currencies rise 6%.Operating profit exceeds last years record by 4%in local currencies,reaching 13.9 billion Swiss francsdespite increased l

6、evel of R&D investment.Net income down by 5%in Swiss francs to 10.8 billion Swiss francs,primarily due to the strong Swissfranc,but also to lower net financial income.Core Earnings per Share at constant exchange rates 2%above previous years record level.PharmaceuticalsPharmaceuticals sales advance 1